Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

44.50USD
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
$44.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
191,691
52-wk High
$67.86
52-wk Low
$29.17

Gentile, Kimberly 

Ms. Kimberly Gentile serves as Vice President - Clinical Operations of the Company. Ms. Gentile has served as our senior vice president, clinical operations since February 2014. Before coming to Biohaven, Ms. Gentile served as associate director, project manager, global clinical operations at BMS from 2000 to February 2014. Prior to this, she was a senior clinical trial manager at SCIREX Corporation from 1996 to June 2000. Ms. Gentile received her B.S. in Psychology from Salem State University.

Basic Compensation

Total Annual Compensation, USD 2,769,350
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 15,192
Fiscal Year Total, USD 2,784,540

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 27,500 960,142.00
Name Fiscal Year Total

Declan Doogan

706,360

Vlad Coric

7,854,000

James Engelhart

3,217,070

Kimberly Gentile

2,784,540

Charles Conway

2,792,860

Robert Berman

521,060
As Of  31 Dec 2018